NEW YORK and CANTON, Mass.,—Avista Healthcare Public Acquisition Corp. (AHPAC) and Organogenesis Inc. have announced that they have entered into a definitive merger agreement, under which Organogenesis will become a wholly owned subsidiary of AHPAC. Affiliates of Avista Capital Partners, a private equity firm, has agreed to invest $92 million in the combined company, in conjunction with the transaction. Following the closing of the transaction, Organogenesis will be listed on the Nasdaq Stock Exchange under the ticker symbol “ORGO.” The combined company will have an anticipated initial enterprise value of approximately $673 million.
Articles
The urge to merge
Avista Healthcare Public Acquisition Corp. to combine with Organogenesis Inc.Brought to you byDDNews Staff
| 2 min read
To continue reading this article, subscribe for FREE to
Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.
Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.
Here are some related topics that may interest you:
NEW YORK and CANTON, Mass.,—Avista Healthcare Public Acquisition Corp. (AHPAC) and Organogenesis Inc. have announced that they have entered into a definitive merger agreement, under which Organogenesis will become a wholly owned subsidiary of AHPAC. Affiliates of Avista Capital Partners, a private equity firm, has agreed to invest $92 million in the combined company, in conjunction with the transaction. Following the closing of the transaction, Organogenesis will be listed on the Nasdaq Stock Exchange under the ticker symbol “ORGO.” The combined company will have an anticipated initial enterprise value of approximately $673 million.
“We are delighted to be partnering with Organogenesis, as the Company is well-positioned to benefit from secular tailwinds driving growth in the Advanced Wound Care, Surgical and Sports Medicine sectors,” said Thompson Dean, Executive Chairman of AHPAC. “Organogenesis represents an ideal partner for AHPAC given its leading position in the large and attractive regenerative medicine sector, numerous growth opportunities and demonstrated ability to execute on product development and commercialization capabilities.”
This transaction will be funded through a combination of cash, stock, and rollover debt financing. Organogenesis’ key existing shareholders will remain committed long-term partners by rolling over their equity into the combined company.
The boards of directors of AHPAC and Organogenesis have unanimously approved the proposed transaction, and shareholders of the company representing approximately 89% of the outstanding stock of the company have agreed to support approval of the proposed transaction in any consent solicitation or shareholders’ meeting in connection with the transaction. Completion of the proposed transaction, which is expected before the end of the year, is subject to customary and other closing conditions, including regulatory approvals and receipt of approvals from AHPAC’s shareholders.
AHPAC is a special purpose acquisition company that completed its initial public offering in October 2016. AHPAC was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or business combination with one or more businesses. AHPAC is sponsored by Avista Acquisition Corp., which was formed for the express purpose of acting as the sponsor for AHPAC. Avista Acquisition Corp. is an affiliate of Avista Capital Holdings, L.P.
Organogenesis Inc. focuses on the development, manufacture and commercialization of product solutions for the Advanced Wound Care, Surgical and Sports Medicine markets, with a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs.
Organogenesis states that their mission is to provide integrated healing solutions that substantially improve medical outcomes and the lives of patients, while lowering the overall cost of care. Today, Organogenesis has over 600 employees worldwide and is led by a management team of talented individuals with more than 75 years of collective regenerative medicine experience.
Gary S. Gillheeney, Sr., President and Chief Executive Officer of Organogenesis, said, “This is an important day in the history of Organogenesis. We look forward to working with Tom Dean, AHPAC and Avista Capital Partners to continue building a successful enterprise. This transaction will provide Organogenesis with capital that we will use to accelerate our growth plan for both our existing product portfolio and R&D pipeline.”
